The rising cost of health care is a concern to most Americans.
If we move forward to Universal Healthcare, can we afford it? Are there cheaper approaches to the most common problems?
For example, depression is common and often requires several trials at great expense to discover workable therapy. The venerable Bonkers Institute for Nearly Genuine Research reveals that a direct approach to what bothers many patients may be one of the most innovative and cost effective remedies yet discovered.
Depression and anxiety are the most common mental disorders in America, affecting more than 60 million patients every year.
Pharmacological interventions dominate the medical management of these disorders and may include selective serotonin reuptake inhibitors (Prozac), norepinephrine reuptake inhibitors (Strattera), monoamine oxidase inhibitors (Emsam), benzodiazepines (Valium), azaspirodecanediones (BuSpar), and any number of similarly efficacious drugs or drug combinations prescribed in accordance with strict FDA guidelines, or not, based on the treating physician’s better judgment.
Since mental illness is a lifelong condition with no known cure, the successful psychopharmacological management of disorders such as depression or anxiety can be challenging. Treatment with medication almost inevitably results in side effects requiring additional medications leading to additional side effects necessitating still more medications in a self-perpetuating cycle that finally ends when the patient dies or the insurance runs out.
This report discusses two cases in which complete symptomatic relief was achieved following the administration of large sums of money to the patients.